A Phase I, Dose Escalation Study of BNC101 (Anti-LGR5 Humanized Monoclonal Antibody) in Patients With Metastatic Colorectal Cancer.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2017
At a glance
- Drugs BNC 101 (Primary)
- Indications Colon cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Bionomics
- 21 Nov 2017 Planned primary completion date changed from 1 Apr 2019 to 1 Jan 2018.
- 21 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Apr 2016 Status changed from not yet recruiting to recruiting.